多发性-话题@MedSci

#多发性#

905篇内容 | 2974人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1890204, encodeId=9abf1890204bc, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=Plos Med：卡非佐米+来那度胺+地塞米松和环磷酰胺用作多发性骨髓瘤移植前诱导化疗的效果和安全性, objectType=article, longId=205699, objectId=a34920569953, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a34920569953, replyNumber=0, likeNumber=101, createdTime=2021-02-09, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a34920569953, moduleTitle=Plos Med：卡非佐米+来那度胺+地塞米松和环磷酰胺用作多发性骨髓瘤移植前诱导化疗的效果和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a34920569953)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890161, encodeId=a5261890161b5, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=华山陈向军、俞海：西尼莫德带给中国多发性硬化患者前沿疗法，新药研发可从四个方向突破, objectType=article, longId=200726, objectId=135f200e2611, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=135f200e2611, replyNumber=0, likeNumber=66, createdTime=2021-06-19, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=135f200e2611, moduleTitle=华山陈向军、俞海：西尼莫德带给中国多发性硬化患者前沿疗法，新药研发可从四个方向突破, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=135f200e2611)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890174, encodeId=f6c818901e4f1, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=Lancet Neurol：高剂量生物素对进行性多发性硬化症患者残疾进展的影响, objectType=article, longId=202555, objectId=37d220255576, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=37d220255576, replyNumber=0, likeNumber=54, createdTime=2021-01-02, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=37d220255576, moduleTitle=Lancet Neurol：高剂量生物素对进行性多发性硬化症患者残疾进展的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=37d220255576)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890136, encodeId=aa0818901369e, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=Blood：MIF是克服多发性骨髓瘤对蛋白酶体抑制剂耐药的生物标志物和靶点, objectType=article, longId=196922, objectId=a78819692202, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a78819692202, replyNumber=0, likeNumber=65, createdTime=2021-01-20, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a78819692202, moduleTitle=Blood：MIF是克服多发性骨髓瘤对蛋白酶体抑制剂耐药的生物标志物和靶点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a78819692202)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890212, encodeId=9fd01890212c0, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=Neurology：多发性硬化新药，可减缓脑萎缩, objectType=article, longId=206344, objectId=6cff206344d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6cff206344d6, replyNumber=0, likeNumber=76, createdTime=2021-09-10, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6cff206344d6, moduleTitle=Neurology：多发性硬化新药，可减缓脑萎缩, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6cff206344d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890222, encodeId=9c251890222dd, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=Eur Radiol：如何评价多发性骨髓瘤的结构与异质性？, objectType=article, longId=207548, objectId=bb0420e548e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bb0420e548e1, replyNumber=0, likeNumber=69, createdTime=2021-04-18, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bb0420e548e1, moduleTitle=Eur Radiol：如何评价多发性骨髓瘤的结构与异质性？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bb0420e548e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890169, encodeId=8e7218901692b, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=FDA授予oNKord®治疗多发性骨髓瘤的“孤儿药称号”, objectType=article, longId=202036, objectId=bead202036d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bead202036d4, replyNumber=0, likeNumber=87, createdTime=2020-10-14, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bead202036d4, moduleTitle=FDA授予oNKord®治疗多发性骨髓瘤的“孤儿药称号”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bead202036d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890210, encodeId=7a3618902101d, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=Br J Cancer：Vismodegib治疗晚期和多发性基底细胞癌患者的回顾性队列研究, objectType=article, longId=206138, objectId=101e206138d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=101e206138d1, replyNumber=0, likeNumber=76, createdTime=2021-02-18, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=101e206138d1, moduleTitle=Br J Cancer：Vismodegib治疗晚期和多发性基底细胞癌患者的回顾性队列研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=101e206138d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890180, encodeId=d350189018002, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=诺诚健华奥布替尼获美国FDA批准开展治疗多发性硬化症临床II期研究, objectType=article, longId=202938, objectId=6e7f20293886, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6e7f20293886, replyNumber=0, likeNumber=74, createdTime=2020-11-07, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6e7f20293886, moduleTitle=诺诚健华奥布替尼获美国FDA批准开展治疗多发性硬化症临床II期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6e7f20293886)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890223, encodeId=03c41890223a3, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=Nat Med：多发性骨髓瘤患者在BCMA靶向CAR-T治疗后或引起BCMA纯合缺失, objectType=article, longId=207579, objectId=380720e5793a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=380720e5793a, replyNumber=0, likeNumber=73, createdTime=2021-12-17, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=380720e5793a, moduleTitle=Nat Med：多发性骨髓瘤患者在BCMA靶向CAR-T治疗后或引起BCMA纯合缺失, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=380720e5793a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890126, encodeId=5a011890126bc, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=血液系统疾病诊断思路图解病例之多发性骨髓瘤, objectType=article, longId=194775, objectId=944c194e75cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=944c194e75cd, replyNumber=0, likeNumber=89, createdTime=2020-12-20, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=944c194e75cd, moduleTitle=血液系统疾病诊断思路图解病例之多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=944c194e75cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890214, encodeId=77e0189021422, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=NICE建议Revlimid（来那度胺）用于初治多发性骨髓瘤患者, objectType=article, longId=206375, objectId=4d882063e57a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d882063e57a, replyNumber=0, likeNumber=82, createdTime=2021-12-04, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d882063e57a, moduleTitle=NICE建议Revlimid（来那度胺）用于初治多发性骨髓瘤患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d882063e57a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890202, encodeId=b495189020219, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=BRAIN：线粒体UQCRC1突变导致常染色体显性帕金森氏症伴多发性神经病, objectType=article, longId=205166, objectId=bbc8205166d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bbc8205166d8, replyNumber=0, likeNumber=108, createdTime=2021-08-23, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bbc8205166d8, moduleTitle=BRAIN：线粒体UQCRC1突变导致常染色体显性帕金森氏症伴多发性神经病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bbc8205166d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890106, encodeId=8c35189010629, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=CAR-T细胞免疫疗法（idecabtagene vicleucel）治疗多发性骨髓瘤, objectType=article, longId=191240, objectId=fac619124043, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fac619124043, replyNumber=0, likeNumber=153, createdTime=2020-09-23, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fac619124043, moduleTitle=CAR-T细胞免疫疗法（idecabtagene vicleucel）治疗多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fac619124043)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890127, encodeId=b775189012ef0, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=Can J Cardiol：儿童多发性大动脉炎若累及冠脉，更易发生冠脉瘤！, objectType=article, longId=194876, objectId=cdd81948e6bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cdd81948e6bb, replyNumber=0, likeNumber=59, createdTime=2020-08-17, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cdd81948e6bb, moduleTitle=Can J Cardiol：儿童多发性大动脉炎若累及冠脉，更易发生冠脉瘤！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cdd81948e6bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890209, encodeId=f7b9189020947, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=Lancet Neurology：Patisiran治疗遗传性甲状腺素运载蛋白介导的多发性神经病性淀粉样变的长期安全性和有效性结果 , objectType=article, longId=206032, objectId=5a4220603291, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5a4220603291, replyNumber=0, likeNumber=77, createdTime=2021-06-24, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5a4220603291, moduleTitle=Lancet Neurology：Patisiran治疗遗传性甲状腺素运载蛋白介导的多发性神经病性淀粉样变的长期安全性和有效性结果 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5a4220603291)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890164, encodeId=77a218901648e, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=Cell Biol Int：鼻内递送SDF-1α预处理的干细胞可改善杯多发性硬化症的再髓鞘化作用, objectType=article, longId=201547, objectId=8ab720154e79, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ab720154e79, replyNumber=0, likeNumber=65, createdTime=2021-04-24, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ab720154e79, moduleTitle=Cell Biol Int：鼻内递送SDF-1α预处理的干细胞可改善杯多发性硬化症的再髓鞘化作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8ab720154e79)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890211, encodeId=ef9f1890211ea, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=英国NICE否定了Zeposia治疗多发性硬化症的作用, objectType=article, longId=206189, objectId=adb420618980, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=adb420618980, replyNumber=0, likeNumber=82, createdTime=2021-07-15, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=adb420618980, moduleTitle=英国NICE否定了Zeposia治疗多发性硬化症的作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=adb420618980)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890159, encodeId=cafe18901590c, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=EBV特异性T细胞免疫疗法ATA188治疗多发性硬化症：所有剂量组均取得积极结果, objectType=article, longId=200586, objectId=adbc20058698, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=adbc20058698, replyNumber=0, likeNumber=95, createdTime=2021-03-19, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=adbc20058698, moduleTitle=EBV特异性T细胞免疫疗法ATA188治疗多发性硬化症：所有剂量组均取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=adbc20058698)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890188, encodeId=0ba5189018876, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=Blood：与多发性骨髓瘤患者感染新冠病毒预后的相关因素, objectType=article, longId=203762, objectId=e06e203e62a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e06e203e62a2, replyNumber=0, likeNumber=92, createdTime=2021-07-02, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e06e203e62a2, moduleTitle=Blood：与多发性骨髓瘤患者感染新冠病毒预后的相关因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e06e203e62a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

多发性

2020-05-29

jml2009 (审核中...)

前往app查看评论内容

#多发性#

Plos Med：卡非佐米+来那度胺+地塞米松和环磷酰胺用作多发性骨髓瘤移植前诱导化疗的效果和安全性

2021-02-09

jml2009 (审核中...)

前往app查看评论内容

#多发性#

华山陈向军、俞海：西尼莫德带给中国多发性硬化患者前沿疗法，新药研发可从四个方向突破

2021-06-19

jml2009 (审核中...)

前往app查看评论内容

#多发性#

Lancet Neurol：高剂量生物素对进行性多发性硬化症患者残疾进展的影响

2021-01-02

jml2009 (审核中...)

前往app查看评论内容

#多发性#

Blood：MIF是克服多发性骨髓瘤对蛋白酶体抑制剂耐药的生物标志物和靶点

2021-01-20

jml2009 (审核中...)

前往app查看评论内容

#多发性#

Neurology：多发性硬化新药，可减缓脑萎缩

2021-09-10

jml2009 (审核中...)

前往app查看评论内容

#多发性#

Eur Radiol：如何评价多发性骨髓瘤的结构与异质性？

2021-04-18

jml2009 (审核中...)

前往app查看评论内容

#多发性#

FDA授予oNKord®治疗多发性骨髓瘤的“孤儿药称号”

2020-10-14

jml2009 (审核中...)

前往app查看评论内容

#多发性#

Br J Cancer：Vismodegib治疗晚期和多发性基底细胞癌患者的回顾性队列研究

2021-02-18

jml2009 (审核中...)

前往app查看评论内容

#多发性#

诺诚健华奥布替尼获美国FDA批准开展治疗多发性硬化症临床II期研究

2020-11-07

jml2009 (审核中...)

前往app查看评论内容

#多发性#

Nat Med：多发性骨髓瘤患者在BCMA靶向CAR-T治疗后或引起BCMA纯合缺失

2021-12-17

jml2009 (审核中...)

前往app查看评论内容

#多发性#

血液系统疾病诊断思路图解病例之多发性骨髓瘤

2020-12-20

jml2009 (审核中...)

前往app查看评论内容

#多发性#

NICE建议Revlimid（来那度胺）用于初治多发性骨髓瘤患者

2021-12-04

jml2009 (审核中...)

前往app查看评论内容

#多发性#

BRAIN：线粒体UQCRC1突变导致常染色体显性帕金森氏症伴多发性神经病

2021-08-23

jml2009 (审核中...)

前往app查看评论内容

#多发性#

CAR-T细胞免疫疗法（idecabtagene vicleucel）治疗多发性骨髓瘤

2020-09-23

jml2009 (审核中...)

前往app查看评论内容

#多发性#

Can J Cardiol：儿童多发性大动脉炎若累及冠脉，更易发生冠脉瘤！

2020-08-17

jml2009 (审核中...)

前往app查看评论内容

#多发性#

Lancet Neurology：Patisiran治疗遗传性甲状腺素运载蛋白介导的多发性神经病性淀粉样变的长期安全性和有效性结果

2021-06-24

jml2009 (审核中...)

前往app查看评论内容

#多发性#

Cell Biol Int：鼻内递送SDF-1α预处理的干细胞可改善杯多发性硬化症的再髓鞘化作用

2021-04-24

jml2009 (审核中...)

前往app查看评论内容

#多发性#

英国NICE否定了Zeposia治疗多发性硬化症的作用

2021-07-15

jml2009 (审核中...)

前往app查看评论内容

#多发性#

EBV特异性T细胞免疫疗法ATA188治疗多发性硬化症：所有剂量组均取得积极结果

2021-03-19

jml2009 (审核中...)

前往app查看评论内容

#多发性#

Blood：与多发性骨髓瘤患者感染新冠病毒预后的相关因素

2021-07-02

科室
- - 订阅+
  - 更多科室
工具
服务